<a href="https://www.fiercebiotech.com/biotech/pfizer-ends-work-phase-1-stage-immunostimulatory-drug-conjugate-cancer-patients" hreflang="en">Pfizer cans work on next-gen conjugate in cancer patients</a>
Pfizer has terminated its phase 1 study of the PD-L1-targeting immunostimulatory drug conjugate PF-08046037 in cancer patients, citing "strategic business reasons" without any safety or efficacy concerns. This decision ends Pfizer's plans for this specific drug, although it does not impact the company's broader research into immunostimulatory drug conjugates.
Pfizer's termination of the phase 1 trial for PF‑08046037 due to "strategic business reasons," rather than safety or efficacy concerns, suggests potential shifts in focus or resource allocation within their oncology pipeline, specifically regarding immunostimulatory drug conjugates (ISACs). For professionals in healthtech and biotech, this highlights the importance of monitoring not just clinical outcomes but also strategic business decisions that can influence the trajectory of drug development and investment opportunities, particularly in innovative areas like ISACs.